This is a Validated Antibody Database (VAD) review about domestic s.. MAPT, based on 71 published articles (read how Labome selects the articles), using MAPT antibody in all methods. It is aimed to help Labome visitors find the most suited MAPT antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Knockout validation
Invitrogen
mouse monoclonal (Tau-5)
  • western blot knockout validation; mouse; 1:1000; loading ...; fig 4b
In order to find no functional or morphological deficits upon tau reduction or depletion in aged mice, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot knockout validation on mouse samples at 1:1000 (fig 4b). PLoS ONE (2016) ncbi
Invitrogen
mouse monoclonal (Tau-5)
  • immunocytochemistry knockout validation; mouse; fig 3
  • immunocytochemistry; human; fig 3
In order to suggest that Tau regulates neuronal pericentromeric heterochromatin integrity, Invitrogen MAPT antibody (Biosource, AHB0042) was used in immunocytochemistry knockout validation on mouse samples (fig 3) and in immunocytochemistry on human samples (fig 3). Sci Rep (2016) ncbi
Invitrogen
mouse monoclonal (Tau-5)
  • western blot; human; 1:1000; loading ...; fig 2a
Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on human samples at 1:1000 (fig 2a). Nat Commun (2020) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:500; loading ...; fig s6e
Invitrogen MAPT antibody (Thermo Fisher, MA5-12808) was used in western blot on mouse samples at 1:500 (fig s6e). Nature (2019) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; 1:1000; loading ...
Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on human samples at 1:1000. elife (2019) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry; mouse; loading ...; fig 1c
Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in immunohistochemistry on mouse samples (fig 1c). Cell Rep (2018) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000; loading ...; fig 8b
Invitrogen MAPT antibody (Thermo Fisher, AHB0042) was used in western blot on mouse samples at 1:1000 (fig 8b). Cancer Res (2018) ncbi
mouse monoclonal (Tau-5)
  • immunocytochemistry; human; 1:500; loading ...; fig 1a
In order to study the involvement of deacetylase HDAC6 in Tau pathology, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in immunocytochemistry on human samples at 1:500 (fig 1a). Cell Rep (2017) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000; loading ...; fig 2A
In order to elucidate how liraglutide affects disease and cognitive function in a mouse model of Alzheimer disease, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on mouse samples at 1:1000 (fig 2A). Neurochem Res (2017) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; loading ...; fig 5a
In order to assess the role of MECP2 in tau pathology using several mouse models, Invitrogen MAPT antibody (Thermo Fisher Scientific, AHB0042) was used in western blot on mouse samples (fig 5a). Front Mol Neurosci (2017) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000; loading ...; fig 4b
In order to evaluate the efficacy of an orally bioactive and brain permeable gamma-secretase inhibitor in a mouse model of Alzheimer's disease, Invitrogen MAPT antibody (Thermo, MA5-12805) was used in western blot on mouse samples at 1:1000 (fig 4b). Nat Commun (2017) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry - frozen section; mouse; 1:100; loading ...; fig 2e
In order to investigate the expression patterns of HA synthases in the murine central nervous system, Invitrogen MAPT antibody (Life Technologies, AHB0042) was used in immunohistochemistry - frozen section on mouse samples at 1:100 (fig 2e). J Alzheimers Dis (2017) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:5000; loading ...; fig 4b
In order to report that docosahexaenoic acid is an inducer of cellular protein aggregates, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on mouse samples at 1:5000 (fig 4b). Exp Mol Med (2017) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; 1:2000; loading ...; fig 7a
In order to see that the granulin Alzheimer's disease risk variant has no significant effects on florbetapir positron emission tomographic amyloid imaging and cerebrospinal fluid Abeta levels, Invitrogen MAPT antibody (Thermo Fisher, AHB0042) was used in western blot on human samples at 1:2000 (fig 7a). Acta Neuropathol (2017) ncbi
mouse monoclonal (Tau-5)
  • western blot knockout validation; mouse; 1:1000; loading ...; fig 4b
In order to find no functional or morphological deficits upon tau reduction or depletion in aged mice, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot knockout validation on mouse samples at 1:1000 (fig 4b). PLoS ONE (2016) ncbi
mouse monoclonal (Tau-5)
  • immunocytochemistry; rat; 1:1000; loading ...; fig s1a
In order to study the role of SNARE machinery in neuronal polarity and selective protein targeting, Invitrogen MAPT antibody (Invitrogen, Tau-5) was used in immunocytochemistry on rat samples at 1:1000 (fig s1a). PLoS ONE (2016) ncbi
mouse monoclonal (Tau-5)
  • immunocytochemistry knockout validation; mouse; fig 3
  • immunocytochemistry; human; fig 3
In order to suggest that Tau regulates neuronal pericentromeric heterochromatin integrity, Invitrogen MAPT antibody (Biosource, AHB0042) was used in immunocytochemistry knockout validation on mouse samples (fig 3) and in immunocytochemistry on human samples (fig 3). Sci Rep (2016) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; loading ...; fig 3d
In order to examine S-guanylation of tau and report its effects on tau aggregation, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on human samples (fig 3d). J Biol Chem (2016) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; fig s3
In order to investigate the axon initial segment in neurological disorders, Invitrogen MAPT antibody (Life Technologies, AHB0042) was used in western blot on human samples (fig s3). Mol Neurodegener (2016) ncbi
mouse monoclonal (Tau-5)
  • immunocytochemistry; human; 1:600; fig 4
  • western blot; human; 1:1000; fig 2
In order to determine modulation of cellular release of tau by FRMD4A-cytohesin signaling, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in immunocytochemistry on human samples at 1:600 (fig 4) and in western blot on human samples at 1:1000 (fig 2). J Cell Sci (2016) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry - frozen section; mouse; 1:500; tbl 1
  • western blot; mouse; 1:500; tbl 1
In order to utilize a time course study of sciatic nerves from aging mice to gain a neurogenic perspective of sarcopenia, Invitrogen MAPT antibody (Biosource International, AHB0042) was used in immunohistochemistry - frozen section on mouse samples at 1:500 (tbl 1) and in western blot on mouse samples at 1:500 (tbl 1). J Neuropathol Exp Neurol (2016) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; fig 2
In order to study enhanced degradation of proteasomal substrates that are associated with neurodegenerative disease and the effect of inactivation of USP14, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on human samples (fig 2). F1000Res (2016) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; 1:10,000; fig 3f
In order to investigate the role of channel gating in mammalian proteasomes, Invitrogen MAPT antibody (Invitrogen, Tau-5) was used in western blot on human samples at 1:10,000 (fig 3f). Nat Commun (2016) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; fig 1
In order to investigate survival and neuronal differentiation of human BM-MSCs by pulsed electromagnetic fields, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on human samples (fig 1). Life Sci (2016) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000; tbl 1
  • western blot; human; 1:1000; tbl 1
In order to study reduction of hyperphosphorilated Tau by beta-secretase 1's targeting implying autophagy actors in 3xTg-AD mice, Invitrogen MAPT antibody (Thermo Fisher, TAU-5) was used in western blot on mouse samples at 1:1000 (tbl 1) and in western blot on human samples at 1:1000 (tbl 1). Front Cell Neurosci (2015) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; fig 3
In order to survey the activation of a synapse weakening pathway by human Val66, not Met66 in proBDNF, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on human samples (fig 3). Pharmacol Res (2016) ncbi
mouse monoclonal (Tau-5)
  • western blot; cat; 1:1000; fig 4
In order to study Alzheimer's disease by use of a domestic cat animal model, Invitrogen MAPT antibody (Life Technologies, TAU-5) was used in western blot on cat samples at 1:1000 (fig 4). Acta Neuropathol Commun (2015) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:5000; fig 5
In order to assess the deletion of Ccr2 and cavity size and tau pathology after mild traumatic brain injury, Invitrogen MAPT antibody (Invitrogen, ahb0042) was used in western blot on mouse samples at 1:5000 (fig 5). J Neuroinflammation (2015) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; 1 mg/ml; fig 10
In order to characterize chronic traumatic encephalopathy to determine if phosphorylated tau is unique in epileptic brain and chronic traumatic encephalopathy, Invitrogen MAPT antibody (Life Technologies, AHB0042) was used in western blot on human samples at 1 mg/ml (fig 10). Brain Res (2016) ncbi
mouse monoclonal (Tau-5)
  • immunoprecipitation; human; fig 1
  • western blot; human; fig 1
In order to investigate the effects of tau acetylation at Lys174, Invitrogen MAPT antibody (Life Technologies, AHB0042) was used in immunoprecipitation on human samples (fig 1) and in western blot on human samples (fig 1). Nat Med (2015) ncbi
mouse monoclonal (Tau-5)
  • western blot; human
In order to test if BAG2 mediates the cold-induced accumulation of phosphorylated tau protein, Invitrogen MAPT antibody (Life Technologies, AHB0042) was used in western blot on human samples . Cell Mol Neurobiol (2016) ncbi
mouse monoclonal (Tau-5)
  • western blot; rat; 1:1000
In order to investigate the involvement of microRNA-195 in the effect of chronic brain hypoperfusion on rodent Cdk5/p25 and tau phosphorylation, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on rat samples at 1:1000. J Neurochem (2015) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; 1:5000; fig 1
In order to elucidate how methylene blue inhibits tau aggregation, Invitrogen MAPT antibody (Biosource, AHB0042) was used in western blot on human samples at 1:5000 (fig 1). Sci Rep (2015) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; fig 4
In order to test the effects of high fat diet using a mouse model of familial Alzheimer disease, Invitrogen MAPT antibody (Biosource, AHB0042) was used in western blot on mouse samples (fig 4). Biochim Biophys Acta (2015) ncbi
mouse monoclonal (Tau-5)
  • western blot; human
In order to investigate the role of Apaf1 in axonogenesis, Invitrogen MAPT antibody (Life Technologies, AHB0042) was used in western blot on human samples . Cell Mol Life Sci (2015) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry - paraffin section; human; 1:500; fig 2
  • western blot; human; 1:1000; fig 4
In order to evaluate motor function and tau pathology of P301S tau transgenic mice, Invitrogen MAPT antibody (Invitrogen, TAU5) was used in immunohistochemistry - paraffin section on human samples at 1:500 (fig 2) and in western blot on human samples at 1:1000 (fig 4). Mol Neurodegener (2014) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; fig 2
In order to use triple transgenic Alzhemier's mice to study short- and long-term CDK5 knockdown and prevention of spatial memory dysfunction and tau pathology, Invitrogen MAPT antibody (Invitrogen, Tau5) was used in western blot on mouse samples (fig 2). Front Aging Neurosci (2014) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:20000
In order to investigate the role of membrane-anchored versus soluble CX3CL1 in regulating the microglia-mediated amelioration of Abeta pathology, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on mouse samples at 1:20000. J Neurosci (2014) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry; mouse; 1:3000
In order to assess if tau reduction benefits intractable genetic epilepsies, Invitrogen MAPT antibody (Life Technologies, tau-5) was used in immunohistochemistry on mouse samples at 1:3000. Ann Neurol (2014) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse
In order to investigate the abnormalites in hippocampal energy metabolism in the pathogenesis of Alzheimer disease, Invitrogen MAPT antibody (Biosource, AHB0042) was used in western blot on mouse samples . Biochim Biophys Acta (2014) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:500
In order to study how induction of Calyculin A in N2a cells can attenuate axonal transport impairment and axonopathy by Berberine, Invitrogen MAPT antibody (NeoMarkers, tau-5) was used in western blot on mouse samples at 1:500. PLoS ONE (2014) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000
In order to investigate the murine tau isoforms in brain and peripheral organs, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on mouse samples at 1:1000. PLoS ONE (2013) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:4000
In order to identify a method for simultaneous use of both biochemistry and immunohistochemistry in regards to the same tissue, Invitrogen MAPT antibody (Thermo Fisher Scientific, Tau-5) was used in western blot on mouse samples at 1:4000. Eur J Neurosci (2014) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry - frozen section; mouse
In order to study the composition of pathological granules that appear in degenerative brain diseases, Invitrogen MAPT antibody (Biosource, AHB0042) was used in immunohistochemistry - frozen section on mouse samples . Age (Dordr) (2014) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; fig 6
In order to test if beta-amyloid accumulation affects prion infectivity and if different amounts of PrP affect beta-amyloid accumulation, Invitrogen MAPT antibody (Invitrogen, #AHB0042) was used in western blot on mouse samples (fig 6). Neurobiol Aging (2013) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; 1:200; fig 2
In order to study the ability of pharmacological activation of AMPK to protect a human neuroblastoma cell line against homocysteine-induced toxicity, Invitrogen MAPT antibody (Lab Vision, MS-247-P0) was used in western blot on human samples at 1:200 (fig 2). Neurochem Res (2013) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry; human; 1:1000
  • western blot; human; 1:1000; fig 3
In order to study changes in autophagy and the roles of Tau hyperphosphorylation and fractalkine in an animal model of Abeta42-induced Tau hyperphosphorylation, Invitrogen MAPT antibody (Thermo Scientific, Tau-5) was used in immunohistochemistry on human samples at 1:1000 and in western blot on human samples at 1:1000 (fig 3). Exp Neurol (2014) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000; fig 6
In order to elucidate the role of dietary resveratrol in SAMP8 mice, Invitrogen MAPT antibody (BioSource, AHB0042) was used in western blot on mouse samples at 1:1000 (fig 6). Age (Dordr) (2013) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; fig 3
In order to investigate the contribution of Ang II to Alzheimer disease, Invitrogen MAPT antibody (Invitrogen, Tau-5) was used in western blot on mouse samples (fig 3). FEBS Lett (2012) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry; rat; 1:2000
In order to examine the brains of 6-month-old rats treated neonatally with the glutamatergic beta-N-methylamino-L-alanine, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in immunohistochemistry on rat samples at 1:2000. Toxicol Sci (2012) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; fig 1
In order to investigate interactions between MAP2 and PP2A/Balpha in the brain, Invitrogen MAPT antibody (BIOSOURCE, Tau-5) was used in western blot on mouse samples (fig 1). J Biol Chem (2012) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry; mouse; fig 3
In order to determine the distribution of tauopathy in different regions of the brain using the alpha-Syn overexpressing mouse model, Invitrogen MAPT antibody (Biosource, AHB0042) was used in immunohistochemistry on mouse samples (fig 3). BMC Neurosci (2011) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; 1:1000; fig 2
In order to test if neurite retraction in the SH-SY5Y model is associated with changes in other tau hyperphosphorylable residues, Invitrogen MAPT antibody (BioSource, AHB0042) was used in western blot on human samples at 1:1000 (fig 2). J Neurosci Res (2011) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; 1:500; fig 2
In order to examine tauopathy in mice that overexpress human alpha-synuclein as a model of Parkinson's disease, Invitrogen MAPT antibody (Invitrogen, AHB0042) was used in western blot on human samples at 1:500 (fig 2). Eur J Neurosci (2011) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:500; fig 3
In order to study the tauopathic changes in the striatum of the alpha-synuclein A53T mutant mouse, Invitrogen MAPT antibody (Biosource, AHB0042) was used in western blot on mouse samples at 1:500 (fig 3). PLoS ONE (2011) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry - paraffin section; rat; 1:1000; fig 5
  • western blot; rat; 1:2000; fig 4
In order to elucidate the molecular mechanisms of ischemic tolerance, Invitrogen MAPT antibody (Biosource, AHB0042) was used in immunohistochemistry - paraffin section on rat samples at 1:1000 (fig 5) and in western blot on rat samples at 1:2000 (fig 4). Neurol Sci (2011) ncbi
mouse monoclonal (Tau-5)
  • western blot; human; 1:1000
In order to elucidate the between tau aggregation and the unfolded protein response in neurodegenerative disorders, Invitrogen MAPT antibody (Biosource, AHB0042) was used in western blot on human samples at 1:1000. J Neurosci Res (2010) ncbi
mouse monoclonal (Tau-5)
  • ELISA; human; fig 1a
In order to test if HFE polymorphisms are associated with alterations in tau phosphorylation in a human neuroblastoma cell line, Invitrogen MAPT antibody (Biosource International, Tau-5) was used in ELISA on human samples (fig 1a). Neurobiol Aging (2011) ncbi
mouse monoclonal (Tau-5)
  • western blot; rat; 1:1000; fig 3
In order to assess the neuroprotective effects of delphinidin against Abeta-induced toxicity, Invitrogen MAPT antibody (Biosource, tau-5) was used in western blot on rat samples at 1:1000 (fig 3). Biosci Biotechnol Biochem (2009) ncbi
mouse monoclonal (Tau-5)
  • western blot; rat; 1:1000
In order to investigate the potential neuroprotective effects of caffeic acid against Abeta-induced toxicity, Invitrogen MAPT antibody (Biosource, tau-5) was used in western blot on rat samples at 1:1000. Life Sci (2009) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000
In order to investigate the neurotoxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin, Invitrogen MAPT antibody (Biosource, tau-5) was used in western blot on mouse samples at 1:1000. Toxicology (2009) ncbi
mouse monoclonal (Tau-5)
  • immunocytochemistry; rat; 1:200
In order to develop an electrophysiologically active 3D neural construct with neurons and astrocytes encased in a bioactive extracellular matrix-based scaffold, Invitrogen MAPT antibody (NeoMarkers, MS247P) was used in immunocytochemistry on rat samples at 1:200. J Neural Eng (2008) ncbi
mouse monoclonal (Tau-5)
  • western blot; rat; 1:1000; fig 6
In order to elucidate the neuroprotective mechanisms by which curcumin protects against Abeta-induced toxicity, Invitrogen MAPT antibody (Biosource, tau-5) was used in western blot on rat samples at 1:1000 (fig 6). Food Chem Toxicol (2008) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000; fig 3
In order to evaluate if OVX/stress affects levels of Alzheimer's disease-related molecules in the mouse hippocampus, Invitrogen MAPT antibody (Invitrogen, TAU- 5) was used in western blot on mouse samples at 1:1000 (fig 3). Neurosci Lett (2008) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000; fig 5
In order to determine that Abeta deposition or oestrogen deficiency increases PP2A phosphorylation to compromise tau dephosphorylation and cause neurofibrillary tangle formation in Alzheimer's disease, Invitrogen MAPT antibody (Biosource, Tau-5) was used in western blot on mouse samples at 1:1000 (fig 5). J Cell Mol Med (2008) ncbi
mouse monoclonal (Tau-5)
  • western blot; rat; 1:5000
In order to evaluate five glycogen synthase kinase-3beta inhibitors and lithium in lowering phosphorylated tau and glycogen synthase kinase-3beta enzyme activity levels in 12-day old postnatal rats, Invitrogen MAPT antibody (BioSource/Invitrogen, tau-5) was used in western blot on rat samples at 1:5000. Br J Pharmacol (2007) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry - frozen section; human; 1:500
  • western blot; human; 1:500
In order to isolate cis-acting regulatory elements for the generation of transgenic zebrafish models of neurodegeneration, Invitrogen MAPT antibody (Biosource, AHB0042) was used in immunohistochemistry - frozen section on human samples at 1:500 and in western blot on human samples at 1:500. Nucleic Acids Res (2007) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; fig 4
In order to identify and investigate Reelin-regulated signaling pathways in the brain, Invitrogen MAPT antibody (Biosource, AHB0042) was used in western blot on mouse samples (fig 4). Mol Cell Biol (2007) ncbi
mouse monoclonal (Tau-5)
  • western blot; rat; 1:1000; fig 3
In order to test if sex hormones prevent tau cleavage and Abeta toxicity, Invitrogen MAPT antibody (Biosource, tau-5) was used in western blot on rat samples at 1:1000 (fig 3). Neuroscience (2007) ncbi
mouse monoclonal (Tau-5)
  • immunohistochemistry - paraffin section; human; 1:10,000; tbl 1
  • western blot; human; 1:10,000; tbl 1
In order to characterize a new mouse model of Alzheimer's disease, Invitrogen MAPT antibody (Biosource, Tau-5) was used in immunohistochemistry - paraffin section on human samples at 1:10,000 (tbl 1) and in western blot on human samples at 1:10,000 (tbl 1). Am J Pathol (2006) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse
In order to assess the effects lithium chloride on cold water stress-induced changes in tau phosphorylation in the mouse hippocampus, Invitrogen MAPT antibody (Biosource, TAU-5) was used in western blot on mouse samples . J Neural Transm (Vienna) (2006) ncbi
mouse monoclonal (Tau-5)
  • western blot; mouse; 1:1000
In order to elucidate how the removal of assembled neurofilaments from axons or misaccumulating neurofilaments in motor neuron cell bodies slows disease in a mouse model of amyotrophic lateral sclerosis, Invitrogen MAPT antibody (BioSource, Tau-5) was used in western blot on mouse samples at 1:1000. Proc Natl Acad Sci U S A (2005) ncbi
mouse monoclonal (Tau-5)
  • western blot; rat
In order to test if calpain cleave the cyclin-dependent kinase 5 activator p35 to a p25 fragment and results in tau hyperphosphorylation, Invitrogen MAPT antibody (BioSource, tau-5) was used in western blot on rat samples . Biochem Biophys Res Commun (2002) ncbi
Articles Reviewed
  1. Silva M, Nandi G, Tentarelli S, Gurrell I, Jamier T, Lucente D, et al. Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons. Nat Commun. 2020;11:3258 pubmed publisher
  2. Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt S, Vieira Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;: pubmed publisher
  3. Silva M, Ferguson F, Cai Q, Donovan K, Nandi G, Patnaik D, et al. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. elife. 2019;8: pubmed publisher
  4. Merezhko M, Brunello C, Yan X, Vihinen H, Jokitalo E, Uronen R, et al. Secretion of Tau via an Unconventional Non-vesicular Mechanism. Cell Rep. 2018;25:2027-2035.e4 pubmed publisher
  5. Quaranta V, Rainer C, Nielsen S, Raymant M, Ahmed M, Engle D, et al. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Cancer Res. 2018;78:4253-4269 pubmed publisher
  6. Tseng J, Xie L, Song S, Xie Y, Allen L, Ajit D, et al. The Deacetylase HDAC6 Mediates Endogenous Neuritic Tau Pathology. Cell Rep. 2017;20:2169-2183 pubmed publisher
  7. Chen S, Sun J, Zhao G, Guo A, Chen Y, Fu R, et al. Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice. Neurochem Res. 2017;42:2326-2335 pubmed publisher
  8. Maphis N, Jiang S, Binder J, Wright C, Gopalan B, Lamb B, et al. Whole Genome Expression Analysis in a Mouse Model of Tauopathy Identifies MECP2 as a Possible Regulator of Tau Pathology. Front Mol Neurosci. 2017;10:69 pubmed publisher
  9. Zhang Z, Obianyo O, Dall E, Du Y, Fu H, Liu X, et al. Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease. Nat Commun. 2017;8:14740 pubmed publisher
  10. Li Y, Li Z, Jin T, Wang Z, Zhao P. Tau Pathology Promotes the Reorganization of the Extracellular Matrix and Inhibits the Formation of Perineuronal Nets by Regulating the Expression and the Distribution of Hyaluronic Acid Synthases. J Alzheimers Dis. 2017;57:395-409 pubmed publisher
  11. Shin S, Kim J, Lee J, Son Y, Lee M, Kim H, et al. Docosahexaenoic acid-mediated protein aggregates may reduce proteasome activity and delay myotube degradation during muscle atrophy in vitro. Exp Mol Med. 2017;49:e287 pubmed publisher
  12. Takahashi H, Klein Z, Bhagat S, Kaufman A, Kostylev M, Ikezu T, et al. Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathol. 2017;133:785-807 pubmed publisher
  13. Van Hummel A, Bi M, Ippati S, van der Hoven J, Volkerling A, Lee W, et al. No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice. PLoS ONE. 2016;11:e0163236 pubmed publisher
  14. Soo Hoo L, Banna C, Radeke C, Sharma N, Albertolle M, Low S, et al. The SNARE Protein Syntaxin 3 Confers Specificity for Polarized Axonal Trafficking in Neurons. PLoS ONE. 2016;11:e0163671 pubmed publisher
  15. Mansuroglu Z, Benhelli Mokrani H, Marcato V, Sultan A, Violet M, Chauderlier A, et al. Loss of Tau protein affects the structure, transcription and repair of neuronal pericentromeric heterochromatin. Sci Rep. 2016;6:33047 pubmed publisher
  16. Yoshitake J, Soeda Y, Ida T, Sumioka A, Yoshikawa M, Matsushita K, et al. Modification of Tau by 8-Nitroguanosine 3',5'-Cyclic Monophosphate (8-Nitro-cGMP): EFFECTS OF NITRIC OXIDE-LINKED CHEMICAL MODIFICATION ON TAU AGGREGATION. J Biol Chem. 2016;291:22714-22720 pubmed
  17. Sohn P, Tracy T, Son H, Zhou Y, Leite R, Miller B, et al. Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Mol Neurodegener. 2016;11:47 pubmed publisher
  18. Yan X, Nykänen N, Brunello C, Haapasalo A, Hiltunen M, Uronen R, et al. FRMD4A-cytohesin signaling modulates the cellular release of tau. J Cell Sci. 2016;129:2003-15 pubmed publisher
  19. Krishnan V, White Z, McMahon C, Hodgetts S, Fitzgerald M, Shavlakadze T, et al. A Neurogenic Perspective of Sarcopenia: Time Course Study of Sciatic Nerves From Aging Mice. J Neuropathol Exp Neurol. 2016;75:464-78 pubmed publisher
  20. Ortuno D, Carlisle H, Miller S. Does inactivation of USP14 enhance degradation of proteasomal substrates that are associated with neurodegenerative diseases?. F1000Res. 2016;5:137 pubmed publisher
  21. Choi W, de Poot S, Lee J, Kim J, Han D, Kim Y, et al. Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation. Nat Commun. 2016;7:10963 pubmed publisher
  22. Urnukhsaikhan E, Cho H, Mishig Ochir T, Seo Y, Park J. Pulsed electromagnetic fields promote survival and neuronal differentiation of human BM-MSCs. Life Sci. 2016;151:130-138 pubmed publisher
  23. Piedrahita D, Castro Álvarez J, Boudreau R, Villegas Lanau A, Kosik K, Gallego Gómez J, et al. β-Secretase 1's Targeting Reduces Hyperphosphorilated Tau, Implying Autophagy Actors in 3xTg-AD Mice. Front Cell Neurosci. 2015;9:498 pubmed publisher
  24. Kailainathan S, Piers T, Yi J, Choi S, Fahey M, Borger E, et al. Activation of a synapse weakening pathway by human Val66 but not Met66 pro-brain-derived neurotrophic factor (proBDNF). Pharmacol Res. 2016;104:97-107 pubmed publisher
  25. Chambers J, Tokuda T, Uchida K, Ishii R, Tatebe H, Takahashi E, et al. The domestic cat as a natural animal model of Alzheimer's disease. Acta Neuropathol Commun. 2015;3:78 pubmed publisher
  26. Gyoneva S, Kim D, Katsumoto A, Kokiko Cochran O, Lamb B, Ransohoff R. Ccr2 deletion dissociates cavity size and tau pathology after mild traumatic brain injury. J Neuroinflammation. 2015;12:228 pubmed publisher
  27. Puvenna V, Engeler M, Banjara M, Brennan C, Schreiber P, Dadas A, et al. Is phosphorylated tau unique to chronic traumatic encephalopathy? Phosphorylated tau in epileptic brain and chronic traumatic encephalopathy. Brain Res. 2016;1630:225-40 pubmed publisher
  28. Min S, Chen X, Tracy T, Li Y, Zhou Y, Wang C, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015;21:1154-62 pubmed publisher
  29. de Paula C, Santiago F, de Oliveira A, Oliveira F, Almeida M, Carrettiero D. The Co-chaperone BAG2 Mediates Cold-Induced Accumulation of Phosphorylated Tau in SH-SY5Y Cells. Cell Mol Neurobiol. 2016;36:593-602 pubmed publisher
  30. Sun L, Ban T, Liu C, Chen Q, Wang X, Yan M, et al. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation. J Neurochem. 2015;134:1139-51 pubmed publisher
  31. Sheik Mohideen S, Yamasaki Y, Omata Y, Tsuda L, Yoshiike Y. Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies. Sci Rep. 2015;5:10821 pubmed publisher
  32. Petrov D, Pedrós I, Artiach G, Sureda F, Barroso E, Pallas M, et al. High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents. Biochim Biophys Acta. 2015;1852:1687-99 pubmed publisher
  33. De Zio D, Molinari F, Rizza S, Gatta L, Ciotti M, Salvatore A, et al. Apaf1-deficient cortical neurons exhibit defects in axonal outgrowth. Cell Mol Life Sci. 2015;72:4173-91 pubmed publisher
  34. Ohia Nwoko O, Montazari S, Lau Y, Eriksen J. Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice. Mol Neurodegener. 2014;9:54 pubmed publisher
  35. Castro Alvarez J, Uribe Arias S, Kosik K, Cardona Gómez G. Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice. Front Aging Neurosci. 2014;6:243 pubmed publisher
  36. Lee S, Xu G, Jay T, Bhatta S, Kim K, Jung S, et al. Opposing effects of membrane-anchored CX3CL1 on amyloid and tau pathologies via the p38 MAPK pathway. J Neurosci. 2014;34:12538-46 pubmed publisher
  37. Gheyara A, Ponnusamy R, Djukic B, Craft R, Ho K, Guo W, et al. Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann Neurol. 2014;76:443-56 pubmed publisher
  38. Pedr s I, Petrov D, Allgaier M, Sureda F, Barroso E, Beas Zarate C, et al. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochim Biophys Acta. 2014;1842:1556-66 pubmed publisher
  39. Liu X, Zhou J, Abid M, Yan H, Huang H, Wan L, et al. Berberine attenuates axonal transport impairment and axonopathy induced by Calyculin A in N2a cells. PLoS ONE. 2014;9:e93974 pubmed publisher
  40. Liu C, Götz J. Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus. PLoS ONE. 2013;8:e84849 pubmed publisher
  41. Notter T, Panzanelli P, PFISTER S, Mircsof D, Fritschy J. A protocol for concurrent high-quality immunohistochemical and biochemical analyses in adult mouse central nervous system. Eur J Neurosci. 2014;39:165-75 pubmed publisher
  42. Manich G, del Valle J, Cabezón I, Camins A, Pallas M, Pelegri C, et al. Presence of a neo-epitope and absence of amyloid beta and tau protein in degenerative hippocampal granules of aged mice. Age (Dordr). 2014;36:151-65 pubmed publisher
  43. Ordóñez Gutiérrez L, Torres J, Gavin R, Anton M, Arroba Espinosa A, Espinosa J, et al. Cellular prion protein modulates ?-amyloid deposition in aged APP/PS1 transgenic mice. Neurobiol Aging. 2013;34:2793-804 pubmed publisher
  44. Park Y, Ko J, Jang Y, Kwon Y. Activation of AMP-activated protein kinase alleviates homocysteine-mediated neurotoxicity in SH-SY5Y cells. Neurochem Res. 2013;38:1561-71 pubmed publisher
  45. Hebron M, Algarzae N, Lonskaya I, Moussa C. Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and A?1-42 gene transfer models. Exp Neurol. 2014;251:127-38 pubmed publisher
  46. Porquet D, Casadesus G, Bayod S, Vicente A, Canudas A, Vilaplana J, et al. Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age (Dordr). 2013;35:1851-65 pubmed publisher
  47. Tian M, Zhu D, Xie W, Shi J. Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett. 2012;586:3737-45 pubmed publisher
  48. Karlsson O, Berg A, Lindström A, Hanrieder J, Arnerup G, Roman E, et al. Neonatal exposure to the cyanobacterial toxin BMAA induces changes in protein expression and neurodegeneration in adult hippocampus. Toxicol Sci. 2012;130:391-404 pubmed publisher
  49. Sontag J, Nunbhakdi Craig V, White C, Halpain S, Sontag E. The protein phosphatase PP2A/B? binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies. J Biol Chem. 2012;287:14984-93 pubmed publisher
  50. Kaul T, Credle J, Haggerty T, Oaks A, Masliah E, Sidhu A. Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's disease. BMC Neurosci. 2011;12:79 pubmed publisher
  51. Maldonado H, Ramírez E, Utreras E, Pando M, Kettlun A, Chiong M, et al. Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes. J Neurosci Res. 2011;89:1489-98 pubmed publisher
  52. Haggerty T, Credle J, Rodriguez O, Wills J, Oaks A, Masliah E, et al. Hyperphosphorylated Tau in an ?-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci. 2011;33:1598-610 pubmed publisher
  53. Wills J, Credle J, Haggerty T, Lee J, Oaks A, Sidhu A. Tauopathic changes in the striatum of A53T ?-synuclein mutant mouse model of Parkinson's disease. PLoS ONE. 2011;6:e17953 pubmed publisher
  54. Nakajima T, Ochi S, Oda C, Ishii M, Ogawa K. Ischemic preconditioning attenuates of ischemia-induced degradation of spectrin and tau: implications for ischemic tolerance. Neurol Sci. 2011;32:229-39 pubmed publisher
  55. Spatara M, Robinson A. Transgenic mouse and cell culture models demonstrate a lack of mechanistic connection between endoplasmic reticulum stress and tau dysfunction. J Neurosci Res. 2010;88:1951-61 pubmed publisher
  56. Hall E, Lee S, Mairuae N, Simmons Z, Connor J. Expression of the HFE allelic variant H63D in SH-SY5Y cells affects tau phosphorylation at serine residues. Neurobiol Aging. 2011;32:1409-19 pubmed publisher
  57. Kim H, Sul D, Lim J, Lee D, Joo S, Hwang K, et al. Delphinidin ameliorates beta-amyloid-induced neurotoxicity by inhibiting calcium influx and tau hyperphosphorylation. Biosci Biotechnol Biochem. 2009;73:1685-9 pubmed
  58. Sul D, Kim H, Lee D, Joo S, Hwang K, Park S. Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. Life Sci. 2009;84:257-62 pubmed publisher
  59. Sul D, Kim H, Cho E, Lee M, Kim H, Jung W, et al. 2,3,7,8-TCDD neurotoxicity in neuroblastoma cells is caused by increased oxidative stress, intracellular calcium levels, and tau phosphorylation. Toxicology. 2009;255:65-71 pubmed publisher
  60. Irons H, Cullen D, Shapiro N, Lambert N, Lee R, LaPlaca M. Three-dimensional neural constructs: a novel platform for neurophysiological investigation. J Neural Eng. 2008;5:333-41 pubmed publisher
  61. Park S, Kim H, Cho E, Kwon B, Phark S, Hwang K, et al. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Food Chem Toxicol. 2008;46:2881-7 pubmed publisher
  62. Fukuzaki E, Takuma K, Himeno Y, Yoshida S, Funatsu Y, Kitahara Y, et al. Enhanced activity of hippocampal BACE1 in a mouse model of postmenopausal memory deficits. Neurosci Lett. 2008;433:141-5 pubmed publisher
  63. Liu R, Zhou X, Tanila H, Bjorkdahl C, Wang J, Guan Z, et al. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med. 2008;12:241-57 pubmed publisher
  64. Selenica M, Jensen H, Larsen A, Pedersen M, Helboe L, Leist M, et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol. 2007;152:959-79 pubmed
  65. Bai Q, Garver J, Hukriede N, Burton E. Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res. 2007;35:6501-16 pubmed
  66. Jossin Y, Goffinet A. Reelin signals through phosphatidylinositol 3-kinase and Akt to control cortical development and through mTor to regulate dendritic growth. Mol Cell Biol. 2007;27:7113-24 pubmed
  67. Park S, Tournell C, Sinjoanu R, Ferreira A. Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons. Neuroscience. 2007;144:119-27 pubmed
  68. Schindowski K, Bretteville A, Leroy K, Bégard S, Brion J, Hamdane M, et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol. 2006;169:599-616 pubmed
  69. Yoshida S, Maeda M, Kaku S, Ikeya H, Yamada K, Nakaike S. Lithium inhibits stress-induced changes in tau phosphorylation in the mouse hippocampus. J Neural Transm (Vienna). 2006;113:1803-14 pubmed
  70. Lobsiger C, Garcia M, Ward C, Cleveland D. Altered axonal architecture by removal of the heavily phosphorylated neurofilament tail domains strongly slows superoxide dismutase 1 mutant-mediated ALS. Proc Natl Acad Sci U S A. 2005;102:10351-6 pubmed
  71. Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttila T. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation. Biochem Biophys Res Commun. 2002;298:693-8 pubmed